Review of Pharmaceutical Benefits Scheme anti-dementia drugs to treat Alzheimers Disease

The Pharmaceutical Benefits Advisory Committee (PBAC) has commissioned a Review of Pharmaceutical Benefits Scheme anti-dementia drugs to treat Alzheimers Disease, and is now inviting submissions to the Review. Further information is available at Review of Pharmaceutical Benefits Scheme anti-dementia drugs to treat Alzheimers Disease, including the Terms of Reference for the Review.